Pure Global

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) - Trial NCT00320398

Access comprehensive clinical trial information for NCT00320398 through Pure Global AI's free database. This Phase 3 trial is sponsored by GlaxoSmithKline and is currently Completed. The study focuses on Thrombosis, Venous. Target enrollment is 114 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT00320398
Phase 3
Completed
drug
Trial Details
ClinicalTrials.gov • NCT00320398
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery

Study Focus

Thrombosis, Venous

Fondaparinux

Interventional

drug

Sponsor & Location

GlaxoSmithKline

Timeline & Enrollment

Phase 3

Jan 30, 2006

Jul 18, 2006

114 participants

Primary Outcome

Percentage of Participants With Venous Thromboembolism (VTE) During Efficacy Period,Percentage of Participants With Major Bleeding

Summary

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

ICD-10 Classifications

Other venous embolism and thrombosis
Embolism and thrombosis of unspecified vein
Embolism and thrombosis of other specified veins
Perianal venous thrombosis
Arterial embolism and thrombosis

Data Source

ClinicalTrials.gov

NCT00320398

Non-Device Trial